Cerebras' First Post-IPO Earnings Beat Wall Street Projections. The Stock Is Falling Anyway

Cerebras beat first-quarter Wall Street estimates with revenue of $193.4 million, about $10 million above consensus, and a narrower-than-expected adjusted loss of $2.48 million. However, shares fell 15% to around $192 as investors focused on softer near-term gross margin guidance of 36% to 38%, down from 47% in Q1. Morgan Stanley remained bullish and raised its price target to $273 from $250.

Analysis

The market is treating this as a classic post-IPO “good quarter, bad setup” event. The key issue is not the earnings beat itself; it is that the company is signaling a near-term gross margin reset while the stock is still priced for scarcity-value growth, so any evidence of cost pressure gets punished harder than top-line upside gets rewarded. In other words, the multiple is being anchored to the next 1-2 quarters of margin trajectory, not the reported quarter.

Second-order, this is a reminder that AI hardware names with custom silicon exposure are now being judged against two competing clocks: revenue growth and manufacturing efficiency. If the margin step-down reflects mix, packaging, or ramp costs, that usually improves later, but the market often discounts that inflection until it shows up in back-to-back quarters. That makes the next catalyst less about beats and more about whether management can prove a stable floor on gross margin before investor patience runs out.

The contrarian read is that the selloff may be larger than fundamentals justify if guidance is intentionally conservative to create future upside. For a newly public name, early guidance tends to be shaped to avoid any “one-and-done” perception, and the analyst community may be underestimating how much demand elasticity exists for differentiated AI compute if the product remains capacity-constrained. The risk, however, is that if margins compress again next quarter, the stock transitions from growth story to credibility problem very quickly.

The cleanest trade is to express skepticism on near-term execution without making a blanket bearish call on AI infrastructure. The asymmetric setup is a short-term put spread or a tactical short into strength, paired against a long in a more diversified AI beneficiary with less gross-margin sensitivity. If margin stabilizes in the next print, the stock could re-rate sharply, but until then the burden of proof is on management to show that revenue growth is not being bought with structurally lower profitability.

Key Decisions for Investors

• Short CBRS tactically on failed bounces over the next 1-2 weeks; target a retest of post-IPO support if margin commentary keeps dominating sentiment. Risk is a sharp squeeze if management reiterates demand strength and sells through the conservative guide.
• Buy CBRS downside via 1-2 month put spreads instead of outright shorts; this limits theta bleed if the stock stabilizes while preserving convexity into the next catalyst. Best if implied vol remains elevated after the print.
• Pair trade: long a diversified AI infrastructure beneficiary (e.g. MS or a broader semis/AI basket) vs. short CBRS for a 1-3 month window. The trade isolates execution risk at a single-name level while keeping exposure to the broader AI capex theme.
• If CBRS revisits IPO price plus 5-10%, take profits on any bearish positioning; the market may be using that zone as a narrative reset level. Above that, the trade becomes a momentum squeeze rather than a fundamentals short.
• Watch the next quarterly margin print as the decisive catalyst; if adjusted gross margin stabilizes above the current guided range, reverse to a small long for a 2-4 quarter mean reversion trade. If it slips again, treat this as a multi-quarter de-rating event.